ReviewJournal of veterinary pharmacology and therapeutics2025
SGLT2 inhibitor use in the management of feline diabetes mellitus.
Review in Journal of veterinary pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats.Journal of feline medicine and surgery · 2025Guideline
- Post-marketing safety monitoring of sodium-glucose cotransporter 2 inhibitors for diabetes in cats: a pharmacovigilance study based on the FDA ADAE database.Journal of veterinary internal medicine · 2026Article
- Pharmacokinetics of Bexagliflozin After Intravenous and Oral Administration in Cats.Journal of veterinary pharmacology and therapeutics · 2026Article
- Guidelines for nutritional management of feline diabetes mellitus: a proposed classification system integrating medical considerations.Journal of feline medicine and surgery · 2026Review
- SGLT2 inhibitor therapy in diabetic cats: first clinical experiences with non-ideal candidates.Journal of feline medicine and surgery · 2026Article
- Use of an automated insulin delivery system in a cat with diabetes mellitus.Journal of veterinary internal medicine · 2026Article
- Owner points of view and perceived quality of life of diabetic cats pre- and post-hypophysectomy for hypersomatotropism.Journal of veterinary internal medicine · 2026Article
- Agreeing Language in Veterinary Endocrinology (ALIVE): Hypothyroidism, Hyperthyroidism, (Euglycaemic) Diabetic Ketosis/Ketoacidosis, and Diabetic Remission-A Modified Delphi-Method-Based System to Create Consensus Definitions.Veterinary sciences · 2026Article
- Factors influencing insulin prescribing practices among small animal specialists.Frontiers in veterinary science · 2026Article
- Clinical therapeutics in feline medicine: updates for old and new drugs.Journal of feline medicine and surgery · 2025Review
- Efficacy and Safety of Non-Insulin Antidiabetic Drugs in Cats: A Systematic Review.Animals : an open access journal from MDPI · 2025Review
- Comparative Pharmacological and Pharmaceutical Perspectives on Antidiabetic Therapies in Humans, Dogs, and Cats.Pharmaceutics · 2025Review
- Agreeing Language in Veterinary Endocrinology (ALIVE): Cushing's Syndrome and Hypoadrenocorticism-A Modified Delphi-Method-Based System to Create Consensus Definitions.Veterinary sciences · 2025Article
- SGLT2 inhibitor use in the management of feline diabetes mellitus.Journal of veterinary pharmacology and therapeutics · 2025Review
- Sodium-glucose co-transporter 2 inhibitors: a pleiotropic drug in humans with promising results in cats.Frontiers in veterinary science · 2025Review
- Article
- Effects of Velagliflozin in 8 Cats With Diabetes Mellitus and Hypersomatotropism.Journal of veterinary internal medicineArticle
- Rational approach to feline medical emergencies: part 2.Journal of feline medicine and surgeryReview
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are routinely used in the management of human type 2 diabetes and have been shown to effectively mitigate hyperglycemia and reduce the risks of cardiovascular and renal compromise. Two SGLT2 inhibitors, namely bexagliflozin and velagliflozin, were recently FDA approved for the treatment of uncomplicated feline diabetes mellitus. These oral hypoglycemic agents are a suitable option for many newly diagnosed cats, with rapid improvements in glycemic control and clinical signs. Suitable candidates must have some residual β-cell function, as some endogenous insulin production is required to prevent ketosis. Appropriate patient selection and monitoring are necessary, and practitioners should be aware of serious complications such as euglycemic diabetic ketoacidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.